Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

6.750 +0.340 (+5.31%)
Streaming Delayed Price Updated: 11:49 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 Next >
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
From Immuneering Corporation
Via GlobeNewswire
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Closing of $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces $25 Million Private Placement
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Corporation Announces Grant of Inducement Award
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
From Immuneering Corporation
Via GlobeNewswire
Immuneering Launches Pancreatic Cancer Advisory Board
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
From Immuneering Corporation
Via GlobeNewswire
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.